Does dual antiplatelet therapy for 30 months reduce stent thrombosis and major adverse cardiovascular and cerebrovascular events in patients after placement of a drug-eluting stent?
Extending dual antiplatelet therapy to 30 months after drug-eluting stent placement reduces ischemic events and stent thrombosis but increases bleeding compared to standard 12-month therapy.
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Mauri et al. (2014) studied this question.